Ivax Glucovance generic approved
Executive Summary
FDA approves Ivax' ANDA for generic version of Bristol-Myers Squibb's Glucovance (glyburide/metformin) with 180 days of marketing exclusivity Feb. 18. Ivax says it is building inventory for launch. Glucovance lost marketing exclusivity Jan. 31. Ivax is in the middle of 180-day exclusivity for metformin extended-release (Bristol's Glucophage XR) (1"The Pink Sheet" Dec. 1, 2003, p. 17)...
You may also be interested in...
Glucovance generics launch
Ivax launches its generic version of Bristol-Myers Squibb's Glucovance (glyburide/ metformin) May 4, triggering 180 days of marketing exclusivity. Par entered the market with an "authorized" generic the same day. Ivax has been building inventory since ANDA approval Feb. 18 (1"The Pink Sheet" Feb. 23, 2004, In Brief)...
Glucophage XR Settlement: Purepac, Ivax Split Generic Profits For 180 Days
Ivax and Purepac's exclusivity rights settlement for a generic version of Glucophage XR means FDA has avoided a legal challenge to its interpretation of first-to-file requirements for new ANDAs compared to amended applications
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.